Ancestral and consensus envelope immunogens for HIV-1 subtype C

Virology

Volumn 352, Issue 2, 2006, Pages 438-449

  Kothe, Denise L ^a   Li, Yingying ^b   Decker, Julie M ^b   Bibollet Ruche, Frederic ^b   Zammit, Kenneth P ^b   Salazar, Maria G ^b   Chen, Yalu ^b   Weng, Zhiping ^b   Weaver, Eric A ^d   Gao, Feng ^d   Haynes, Barton F ^d   Shaw, George M ^a,b,c   Korber, Bette T M ^e,f   Hahn, Beatrice H ^a,b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

^f SANTA FE INSTITUTE   (United States)

Author keywords

Centralized HIV 1 immunogens; HIV 1 envelope glycoprotein; HIV 1 genetic variation; Subtype C

Indexed keywords

DNA VACCINE; ENVELOPE PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; PLASMID DNA; RECOMBINANT PROTEIN; VIRUS DNA; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CODON USAGE; CONSENSUS; CONTROLLED STUDY; ENVELOPE GENE; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENETIC VARIABILITY; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE; VIRION; VIRUS INFECTION; VIRUS TITRATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CONSENSUS SEQUENCE; CROSS REACTIONS; EVOLUTION, MOLECULAR; GENE PRODUCTS, ENV; GENES, ENV; GUINEA PIGS; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PHYLOGENY; SEQUENCE HOMOLOGY, AMINO ACID;

ANIMALIA; CAVIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33747041588     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.05.011     Document Type: Article

References (47)

1. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., and Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72 (1998) 1497-1503
2. Binley J.M., Sanders R.W., Master A., Cayanan C.S., Wiley C.L., Schiffner L., Travis B., Kuhmann S., Burton D.R., Hu S.L., Olson W.C., and Moore J.P. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 76 (2002) 2606-2616
3. Burgers W.A., van Harmelen J.H., Shephard E., Adams C., Mgwebi T., Bourn W., Hanke T., Williamson A.L., and Williamson C. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J. Gen. Virol. 87 (2006) 399-410
4. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004) 233-236
5. Chakrabarti B.K., Ling X., Yang Z.Y., Montefiori D.C., Panet A., Kong W.P., Welcher B., Louder M.K., Mascola J.R., and Nabel G.J. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 23 (2005) 3434-3445
6. Chen Z., Huang Y., Zhao X., Skulsky E., Lin D., Ip J., Gettie A., and Ho D.D. Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina). J. Virol. 74 (2000) 6501-6510
7. Chohan B., Lang D., Sagar M., Korber B., Lavreys L., Richardson B., and Overbaugh J. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79 (2005) 6528-6531
8. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., Kappes J.C., Shaw G.M., and Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74 (2000) 8358-8367
9. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., and Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 (2004) 2019-2022
10. Doria-Rose N.A., Learn G.H., Rodrigo A.G., Nickle D.C., Li F., Mahalanabis M., Hensel M.T., McLaughlin S., Edmonson P.F., Montefiori D., Barnett S.W., Haigwood N.L., and Mullins J.I. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 79 (2005) 11214-11224
11. Douek D.C., Kwong P.D., and Nabel G.J. The rational design of an AIDS vaccine. Cell 124 (2006) 677-681
12. Ellenberger D.L., Li B., Lupo L.D., Owen S.M., Nkengasong J., Kadio-Morokro M.S., Smith J., Robinson H., Ackers M., Greenberg A., Folks T., and Butera S. Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology 302 (2002) 155-163
13. Gao F., Li Y., Decker J.M., Peyerl F.W., Bibollet-Ruche F., Rodenburg C.M., Chen Y., Shaw D.R., Allen S., Musonda R., Shaw G.M., Zajac A.J., Letvin N., and Hahn B.H. Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Res. Hum. Retroviruses 19 (2003) 817-823
14. Gao F., Weaver E.A., Lu Z., Li Y., Liao H.X., Ma B., Alam S.M., Scearce R.M., Sutherland L.L., Yu J.S., Decker J.M., Shaw G.M., Montefiori D.C., Korber B.T., Hahn B.H., and Haynes B.F. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J. Virol. 79 (2005) 1154-1163
15. Garber D.A., Silvestri G., and Feinberg M.B. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet, Infect. Dis. 4 (2004) 397-413
16. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B.H., Bhattacharya T., and Korber B. Diversity considerations in HIV-1 vaccine selection. Science 296 (2002) 2354-2360
17. Grundner C., Li Y., Louder M., Mascola J., Yang X., Sodroski J., and Wyatt R. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331 (2005) 33-46
18. Haas J., Park E.C., and Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6 (1996) 315-324
19. Haynes B.F., Ma B., Montefiori D.C., Wrin T., Petropoulos C., Sutherland L.L., Scearce R.M., Denton C., Xia S.-M., Korber B.T., and Liao H.-X. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology 345 (2006) 44-55
20. HIV Vaccine Trials Network. http://www.hvtn.org (accessed March 1, 2006).
21. Huang C.C., Stricher F., Martin L., Decker J.M., Majeed S., Barthe P., Hendrickson W.A., Robinson J., Roumestand C., Sodroski J., Wyatt R., Shaw G.M., Vita C., and Kwong P.D. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 13 (2005) 755-768
22. IAVI database of AIDS vaccines in human trials. IAVI Report. http://www.iavi.org/trialsdb (accessed March 1, 2006).
23. Joseph J., Etcheverry F., Alcami J., and Maria G.J. A safe, effective and affordable HIV vaccine-an urgent global need. AIDS Rev. 7 (2005) 131-138
24. Kong W.P., Huang Y., Yang Z.Y., Chakrabarti B.K., Moodie Z., and Nabel G.J. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77 (2003) 12764-12772
25. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 (2005) 10108-10125
26. Li B., Decker J.M., Johnson R.W., Bibollet-Ruche F., Wei X.-P., Mulenga J., Allen S., Hunter E., Hahn B.H., Shaw G.M., Blackwell J.L., and Derdeyn C.A. High autologous neutralizing antibody titers in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 80 (2006) 5211-5218
27. Lian Y., Srivastava I., Gomez-Roman V.R., Zur Megede J., Sun Y., Kan E., Hilt S., Engelbrecht S., Himathongkham S., Luciw P.A., Otten G., Ulmer J.B., Donnelly J.J., Rabussay D., Montefiori D., van Rensburg E.J., and Barnett S.W. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 79 (2005) 13338-13349
28. Liao, H.-X., Sutherland, L.L., Xia, S.-M., Brock, M.E., Scearce, R.M., Vanleeuwen, S., Alam, S.M., McAdams, M., Weaver, E.A., Ma, B.-J., Li, Y., Decker, J.M., Nabel, G.J., Montefiori, D.C., Hahn, B.H., Korber, B.T., Gao, F., Haynes, B.F., in press. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology.
29. Morris L., Cilliers T., Bredell H., Phoswa M., and Martin D.J. CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res. Hum. Retroviruses 17 (2001) 697-701
30. Mullins J.I., Nickle D.C., Heath L., Rodrigo A.G., and Learn G.H. Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Rev. Vaccines 3 (2004) S151-S159
31. Nickle D.C., Jensen M.A., Gottlieb G.S., Shriner D., Learn G.H., Rodrigo A.G., and Mullins J.I. Consensus and ancestral state HIV vaccines. Science 299 (2003) 1515-1518
32. Nkolola J.P., and Essex M. Progress towards an HIV-1 subtype C vaccine. Vaccine 24 (2006) 391-401
33. Novitsky V., Smith U.R., Gilbert P., McLane M.F., Chigwedere P., Williamson C., Ndung'u T., Klein I., Chang S.Y., Peter T., Thior I., Foley B.T., Gaolekwe S., Rybak N., Gaseitsiwe S., Vannberg F., Marlink R., Lee T.H., and Essex M. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?. J. Virol. 76 (2002) 5435-5451
34. Osmanov S., Pattou C., Walker N., Schwardlander B., and Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquired Immune Defic. Syndr. 29 (2002) 184-190
35. Pancera M., Lebowitz J., Schon A., Zhu P., Freire E., Kwong P.D., Roux K.H., Sodroski J., and Wyatt R. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J. Virol. 79 (2005) 9954-9969
36. Peeters M., Vincent R., Perret J.L., Lasky M., Patrel D., Liegeois F., Courgnaud V., Seng R., Matton T., Molinier S., and Delaporte E. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 20 (1999) 115-121
37. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., and Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72 (1998) 2855-2864
38. Rasmussen R.A., Ong H., Kittel C., Ruprecht C.R., Ferrantelli F., Hu S.L., Policano P., McKenna J., Moon J., Travis B., and Ruprecht R.M. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice. Vaccine 24 (2006) 2324-2332
39. Schneider R., Campbell M., Nasioulas G., Felber B.K., and Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J. Virol. 71 (1997) 4892-4903
40. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., and Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J. Virol. 66 (1992) 7176-7182
41. Seaman M.S., Xu L., Beaudry K., Martin K.L., Beddall M.H., Miura A., Sambor A., Chakrabarti B.K., Huang Y., Bailer R., Koup R.A., Mascola J.R., Nabel G.J., and Letvin N.L. Multiclade human immunodeficiency virus type I envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79 (2005) 2956-2963
42. Spenlehauer C., Gordon C.A., Trkola A., and Moore J.P. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. Virology 280 (2001) 292-300
43. Srivastava I.K., VanDorsten K., Vojtech L., Barnett S.W., and Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77 (2003) 2310-2320
44. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22 (1994) 4673-4680
45. Weaver, E.A., Lu, Z., Camacho, Z.T., Moukdar, F., Liao, H.-X., Ma, B.-J., Muldoon, M., Theiler, J., Nabel, G.J., Letvin, N.L., Korber, B. T., Hahn, B.H., Haynes, B.F., Gao, F., in press. Cross-subtype T cell immune responses induced by an HIV-1 group M Consensus Env immunogen. J. Virol.
46. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 (2002) 1896-1905
47. Zhang Y., Lou B., Lal R.B., Gettie A., Marx P.A., and Moore J.P. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74 (2000) 6893-6910